Spots Global Cancer Trial Database for An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
Official Title: An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
Study ID: NCT01969695
Conditions
Interventions
Study Description
Brief Summary: This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States
Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States
Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
